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Diabetic nephropathy remains one of the most important
causes of end-stage renal disease. This is particularly true
for women from racial/ethnic minorities. Although
administration of 17b-estradiol to diabetic animals has been
shown to reduce extracellular matrix deposition in glomeruli
and mesangial cells, effects on podocytes are lacking. Given
that podocyte injury has been implicated as a factor leading
to the progression of proteinuria and diabetic nephropathy,
we treated db/db mice, a model of type 2 diabetic
glomerulosclerosis, with 17b-estradiol or tamoxifen to
determine whether these treatments reduce podocyte injury
and decrease glomerulosclerosis. We found that albumin
excretion, glomerular volume, and extracellular matrix
accumulation were decreased in these mice compared to
placebo treatment. Podocytes isolated from all treatment
groups were immortalized and these cell lines were found to
express the podocyte markers WT-1, nephrin, and the TRPC6
cation channel. Tamoxifen and 17b-estradiol treatment
decreased podocyte transforming growth factor-b mRNA
expression but increased that of the estrogen receptor
subtype b protein. 17b-estradiol, but not tamoxifen,
treatment decreased extracellular-regulated kinase
phosphorylation. These data, combined with improved
albumin excretion, reduced glomerular size, and decreased
matrix accumulation, suggest that both 17b-estradiol and
tamoxifen may protect podocytes against injury and
therefore ameliorate diabetic nephropathy.
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Diabetic nephropathy is the major cause of end-stage renal
disease and an increasing economic burden in the world. The
female-to-male incidence ratio of end-stage renal disease
caused by diabetic glomerulosclerosis (GS) is higher in post-
menopausal than in pre-menopausal women compared with
men of the same age.1 This is particularly true for women
from racial–ethnic minorities in the United States. The
glomerulus is an estrogen target tissue, and 17b-estradiol (E2)
prevents the onset or slows the development and/or
progression of GS in mouse models of progressive kidney
disease.2–5 To date, the molecular mechanisms underlying the
beneficial effects of E2 or tamoxifen, an estrogen receptor
(ER) modulator, on the glomerulus in vitro have been limited
to studies on mesangial cells.5–13 E2 treatment prevents the
development of albuminuria in experimental models of
diabetes,3,14 and as podocyte damage is associated with
albumin excretion, we undertook this study to determine
whether E2 or tamoxifen treatment altered the expression of
ERs in glomeruli and podocytes, and in the signaling
pathways that are important in the regulation of apoptosis
and inflammation in isolated podocytes.
Several studies have implicated podocyte injury as one of
the factors leading to the progression of diabetic nephro-
pathy.15 The loss of podocytes either though detachment,
apoptosis, or changes in proliferation leads to proteinuria and
eventually to GS.15 Thus, the development of podocyte cell
lines, established from diabetic models, could aid in elucidat-
ing the mechanisms underlying podocyte injury in diabetes.
We established a method for isolating and propagating
primary mouse podocytes from the glomeruli of young and
old diabetic and normal mice. We used elements of the
techniques suggested by Shankland et al.16 utilizing magnetic
beads. However, the ability to maintain long-term cultures of
mouse podocytes required immortalization with the E6/E7
open reading frame of the human papilloma virus-16, a
method successfully used to immortalize and maintain
most aspects of the normal phenotype in retinal pigmented
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epithelial cells, endothelial cells, and bone marrow cells.17,18
Conditionally immortalized podocytes that retain in vivo
characteristics of differentiated podocytes have also been
cultured from the Immortomouse.16 Others have isolated
podocytes from wild-type and transgenic mice and
humans,16,19 but this is the first description of podocytes
isolated from diabetic mice that have been treated in vivo.
RESULTS
The db/db mice were treated from 7 to 24 weeks of age with
either placebo, E2 (0.05 mg), or tamoxifen (0.05 mg). The
dose of E2 was chosen to obtain blood levels similar to that
found during estrous.20 All the db/db mice were obese
and had stable diabetes at the initiation of treatment. There
were no differences in body weight, kidney weight, or in the
kidney weight–body weight ratio between any of the studied
groups (Table 1). After supplementation, uterine weight was
assessed as a measure of estrogen replacement efficiency.
Uterine weight increased with E2 (Table 1). This correlated
with an increase in the 17b-estradiol levels. Tamoxifen did
not lead to an increase in uterine weight, reinforcing earlier
data of its tissue–organ specific action.21
Glycemia
Glycemia and hemoglobin A1C were similar between the
groups.
Urinary albumin excretion rate is reduced after treatment
with either E2 or tamoxifen
Albumin excretion decreased in mice treated with E2
(0.035±0.003) and tamoxifen (0.045±0.016) compared
with that of placebo-treated control mice (0.25±0.05,
Figure 1).
Glomerular volume and collagen deposition
E2- and tamoxifen-treated mice had decreased glomerular
volume (Figure 2) compared with that of the placebo-treated
control (917,991±65,079, 1.23 106±139,089, and
1.96 106±113,895 mm3, respectively). Although collagen
type IV deposition was decreased in both treatments,
(Figure 3) the reduction of this molecule in the tamoxifen-
treated group, compared with that in the E2-treated group,
was not as marked (3þ staining for placebo-treated group,
Table 1 | Body weight, kidney weight, uterine weight, and estradiol levels
Placebo E2 (0.05) Tam (0.05)
N 12 4 9
Body weight (g) 65±4.4 62±4.1 59±6.2
Kidney weight (g) 0.34±0.04 0.40±0.01 0.30±0.05
Kidney weight–Body weight ratio (g) 0.005±0.008 0.006±0.0005 0.005±0009
Uterus weight (g) 0.035±0.013 0.139±0.07** 0.04±0.01
HbA1c at the time of killing 6.85±1.45 6.05±1.2 6.0±1.7
Serum estradiol concentrations pg/ml (±s.e.m) 13.5±0.7 18.8±1.8* 16.0±0.8
Hb A1c, hemoglobin A1c; Tam, tamoxifen.
*Po0.05 compared with placebo.
**Po0.005 compared with placebo.
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Figure 1 | Urinary albumin excretion did not increase in db/db
diabetic mice after treatment with either E2 or tamoxifen.
Urine albumin excretion was reduced at the time of killing (24
weeks) in db/db diabetic mice treated with E2 or tamoxifen. Data
are expressed as mg albumin/mg creatinine. *Po0.05, **Po0.005
compared with placebo-treated group, n¼ 5–7 mice per group.
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Figure 2 | E2 and tamoxifen treatment reduces glomerular
volume. The glomerular volume of E2-treated or tamoxifen-
treated mice is decreased compared with placebo control
db/db diabetic mice. **Po0.005, ***Po0.0001; n¼ 5–7 mice
per group.
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1þ staining for the E2-treated group, and 2þ staining for
the tamoxifen-treated group). Laminin followed the same
pattern (data not shown).
Podocytes retain their in vivo markers before and after
immortalization
We isolated and propagated podocytes from microdissected
glomeruli of female db/db 24-week-old mice. Zona occludens
(ZO1), an epithelial marker, and nephrin, a specific podocyte
marker, were present on podocytes in vitro. These markers were
also present after cells were immortalized (Figure 4a and b).
Moreover, western analysis revealed the presence of a nephrin
protein (Figure 4c), as well as a TRPC6 ion channel (Figure 4d)
and a WT-1 protein (Figure 4e).22 The expressions of WT-1
and nephrin were also confirmed by real-time reverse
transcription-polymerase chain reaction. These markers were
present with increasing passage and in cells isolated from all
treatment groups. WT-1 mRNA was not altered by treatment
with either E2 or tamoxifen (data not shown).
Real-time polymerase chain reaction
There was no change in podocyte ERa or in ERb copy
number with either E2 or tamoxifen treatment (Table 2).
However, the transforming growth factor-b (TGFb) mRNA
expression was decreased in podocytes isolated from all
treated mice compared with placebo-treated mice (71.5±9.8
and 24.9±6.7, respectively for E2 and tamoxifen treatment
compared with placebo). Unexpectedly, tamoxifen treatment
reduced the TGFb mRNA expression by 75% compared with
25% by E2 treatment.
Estrogen and tamoxifen modulate podocyte ERb protein
expression
The ERa protein expression was not regulated by treatment
with either E2 or tamoxifen, consistent with the mRNA data.
In contrast, the ERb protein expression was increased
after both E2 and tamoxifen treatment (Figure 5a and 5b,
*Po0.05, **Po0.005).
Estrogen and tamoxifen differentially regulate the
phosphorylation of ERK and in podocytes
We found that E2 decreased extracellular signal-regulated
protein kinase (ERK) (Figure 6b and c, *Po0.05) phos-
phorylation, whereas tamoxifen had no effect on it.
MMP-2 (matrix metalloproteinase-2) and MMP-9 profile:
Cells isolated from E2-treated mice showed increased MMP-2
(297±18%, Figure 7a) and MMP-9 (138±7%, Figure 7b)
activities compared with the cells from placebo-treated mice.
Cells isolated from tamoxifen-treated mice showed increased
MMP-2 (223±41%) and MMP-9 (170±11%) activities
compared with the cells isolated from placebo-treated mice.
DISCUSSION
The glomerulus and isolated mesangial cells are estrogen
targets.5,13,23 Estrogen partially blocks the development of
GS,2–5 and hormone replacement therapy results in decreased
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Figure 3 | Collagen type IV deposition is reduced in the glomeruli of E2-and tamoxifen-treated db/db mice. Representative kidney
sections of diabetic db/db mice: (a) placebo, (b) E2, or (c) tamoxifen at the time of killing (6 months of age). Original magnification 400.
n¼ 3 sections per group. (d) A representative scatter plot shows the number of pixels on stained sections as measured using the NIH Image J.
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proteinuria and improvement of the creatinine clearance in
post-menopausal women with diabetes mellitus.24 There are
no clinical reports on the effects of tamoxifen on kidney
disease. However, as diabetic women have an increased
incidence of breast cancer, they may be treated with
tamoxifen.25
Although treatment with both E2 and tamoxifen reduces
urinary albumin excretion, as well as glomerular volume and
collagen deposition in ROP/Osþ mice,5 the tamoxifen
effects were not as robust as those of E2. As in this study,
tamoxifen treatment was found to decrease renal inflamma-
tion and reduce proteinuria in the NZB/W mice.26
Podocytes play a pivotal role in diabetic kidney changes in
experimental animals and humans.15,27–29 In patients with type
II diabetes, podocyte number and decreased podocyte density
is correlated with GS.30 Podocytes have not earlier been
isolated from type-II-diabetic mice. We isolated, propagated,
and immortalized podocyte cell lines from a 24-week-old
placebo, as well as from E2- and tamoxifen-treated db/db B6
mice. The lines retained many of their in vivo markers after
immortalization. As glomerular cells from mice with several
different forms of GS have stable phenotypic changes,5,31–33 the
responses of podocytes from diabetic mice must be compared
with those from normal mice.
ERs, found to be localized on podocytes by histochemical
studies,34 are regulated by the levels of E2.
5,23,35,36 We found
that E2 and tamoxifen mediate changes in the podocyte
ERa–ERb ratio. Neither ERa copy number nor protein
expression was regulated by E2 or tamoxifen in podocytes.
Although we found no change in ERb mRNA copy number,
the ERb protein expression increased after E2 or tamoxifen
treatment, suggesting that there was a post-translational
regulation, such as protein stabilization.37,38 As the ERb
expression regulates apoptosis and cell cycle in breast cancer
cells,39 the increase in the ERb protein expression in
podocytes could lead to cell cycle changes and increased cell
survival, an effect which could modulate podocyte depletion
in diabetic nephropathy.
TGFb is thought to promote diabetic GS,40–43 and we
found that E2 and tamoxifen treatment reduced the TGFb
mRNA expression.5 TGFb production in isolated mouse
podocytes increases after exposure to high glucose or
Angiotensin II,44 and treatment with an anti-TGFb antibody
shortly after the onset of diabetes reduced albumin excretion
and protected against podocyte loss.45 We now find that the
decreased TGFb mRNA expression and the change in
podocyte ER expression correlated with an improved kidney
function. TGFb signaling pathways, which might be regulated
by, either E2 and/or tamoxifen include three subfamilies of
the mitogen-activated protein kinase family. Mitogen-
activated protein kinases can regulate TGFb signaling
through cross talk with Smads.46–48 We found that E2 treat-
ment decreased the activation of ERK. These data corrobo-
rate earlier immunohistochemical findings that activated
ERK is present in podocytes of diabetic kidneys, and is
correlated with the severity of glomerular lesions.49 As TGFb
activated the ERK signaling, and as ERK cross talk with Smad
enhanced the TGFb-induced collagen type I expression in
human mesangial cells,46,47 this study suggests that the
reduced TGFb expression could decrease ERK activation.
Although hyperactivation of mitogen-activated protein
kinase in breast cancer cells reduces the ERa expression,50
we found that reduced the ERa expression was associated
with ERK activation in mesangial cells isolated from diabetic
db/db mice.9 It is possible that E2 reduces ERK expression,
leading to an enhanced ERb protein expression in treated
podocytes. However, E2 responses are cell and tissue specific,
as we and others have shown.5,38,51
1 2 3 4
Figure 4 | Podocytes isolated from diabetic db/db mice retain
expression of in vivo markers. Immunofluorescence staining of
(a) ZO-1 and (b) nephrin. Cell lysates were collected and western
blot analysis was performed for (c) nephrin protein expression,
(d) TRPC expression, and (e) WT-1 expression. Cells isolated from a
placebo-treated non-transfected mouse (lane 1), and transfected
(lane 2), cells isolated from E2 (lane 3), and tamoxifen (lane 4)
treated mice.
Table 2 | mRNA expression of steroid hormone receptors and
TGFb in isolated podocytes
Molecule %
of placebo
ERa
(copy number)
ERb
(copy number) TGFb/18s
Placebo 2855±721 174±16 100
17b-estradiol 3073±744 336±24 71.5±9.8*
Tamoxifen 2224±510 232±24 24.9±6.7**
TGFb, transforming growth factor-b.
*Po0.05 compared with placebo.
**Po0.005 compared with placebo.
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In contrast to E2 treatment, tamoxifen treatment did not
affect ERK activation. These findings suggest that tamoxifen
treatment regulates different signaling pathways when
compared with E2. These data may partly explain the finding
that although both E2 and tamoxifen decrease albumin
excretion, glomerular volume, and TGFb expression, as well
as increase ERb expression, E2 is more effective than
tamoxifen.
MMPs are crucial in the maintenance of the balance
between extracellular matrix synthesis and degradation in
glomeruli,52 and mesangial cell MMP-2 activity and tran-
scriptional activation is regulated by continuous in vivo E2
treatment.5 Maric and colleagues14 were the first to report
that MMP-2 is upregulated after E2 treatment in a rat model
of type I diabetes. This is the first report to show that in vivo
treatment with E2 may participate in the remodeling of
glomerular basement membranes through MMP production,
as collagen and laminin deposition were reduced in the
glomeruli of treated mice.
In summary, podocytes isolated from db/db mice, a model
of type II diabetes, may be an important tool for studying the
cellular responses to protective or injurious stimuli in
diabetic GS. Our data suggest that E2 and tamoxifen may
protect against diabetic GS by modulating the phenotype of
podocytes in diabetes by (1) changing the ERa–ERb ratio and
(2) modulating apoptotic and anti-inflammatory signaling
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Figure 5 | Estrogen receptor-b expression is increased in podocytes isolated from E2-and tamoxifen-treated mice. Podocyte cell
lysates were collected and western blot analysis was performed as described in Methods. (a) There was no change in ERa protein expression
in podocytes isolated from mice treated with E2 (lane 3) or tamoxifen (lanes 4 and 5) compared with placebo-treated mice (lane 2).
Immortalization did not alter ERa protein expression (lane 1) or recombinant ERa protein (lane 6), n¼ 2. Data are graphed as the
mean±s.e.m % of placebo ERa protein expression. (b) Estrogen receptor-b was increased in podocytes isolated from mice treated with E2
(lane 2) and tamoxifen (lane 3) compared with placebo-treated mice (lane 1). Data are graphed as the mean±SEM % of placebo ERb protein
expression. n¼ 3, *Po0.05, **Po0.005. Arrows denote specific bands.
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Figure 6 | ERK activation is decreased in cells isolated from E2-treated mice. Cell lysates were collected in duplicate from podocyte cell
lines isolated from placebo, E2 and tamoxifen-treated mice. (a) Representative western blot of pERK and ERK. (b) Data are graphed as
mean±s.e.m ratio of pERK–ERK % of placebo-treated cells. *Po0.05, **Po0.005 compared with placebo treatment. n¼ 3 experiments using
duplicate wells/treatment.
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pathways. The data also suggest that tamoxifen may provide
protection against diabetic nephropathy.
METHODS
Animal Model and Killing
Female C57BL/6J db/db mice were purchased from Jackson
laboratories (Bar Harbor, ME, USA). At 8 weeks of age, they
received a 90-day release subcutaneous pellet of placebo, 17b-
estradiol (E2), or tamoxifen (Innovative Research of America,
Sarasota, FL, USA). Mice were killed at 24 weeks of age and
their left kidney was perfused with a buffer solution
containing collagenase and RNase inhibitors for microdissec-
tion of glomeruli. Their right kidney was perfused in situ with
6 ml of phosphate-buffered saline and 3 ml of 4% parafor-
maldehyde, postfixed in 4% paraformaldehyde solution for at
least 12 h, and embedded in methacrylate. Sections of 4 mm
were stained with periodic acid-Schiff stain.
Measurements of Urinary Albumin and Creatinine
Urine samples were collected monthly and at the time of
killing. Albumin excretion was measured by enzyme-linked
immunosorbent assay (Bethyl Laboratories, Montgomery,
TX, USA), corrected for creatinine concentration in the urine
(kit using the Jaffe method; Stanbio, San Antonio, TX, USA),
and expressed as the mg albumin/mg creatinine (albumin
excretion rate).
Morphometry
A morphometric approach was used to quantify the degree of
GS.53 A total of 50 cortical glomeruli, randomly selected from
a periodic acid-Schiff -stained section from each mouse were
recorded using an Olympus BH-2 microscope and a Micro
Image A209RGB color video camera. Glomerular volume
(mm3) was measured using the MetaMorph 4.5.4 Imaging
System computer program (Universal Imaging Corporation,
West Chester, PA, USA).
Immunohistochemistry
Endogenous peroxidase was blocked in deparaffinized kidney
sections (4 mm). Sections were stained using either rabbit
anti-mouse collagen type IV (Biodesign, Saco, ME, USA) or
rabbit anti-mouse laminin (Research Diagnostics, Flanders,
NJ, USA) as described earlier.8 The sections were examined
and graded on a scale of 0–4þ by a renal pathologist blinded
to the origin of the kidney slides. In addition, collagen was
measured semi-quantitatively by calculating the amount of
pixels on the stained section using NIH (National Institutes
of Health, Bethesda, MD, USA) Image J version 1.6.
Podocyte Isolation
Glomeruli were microdissected and placed in Dulbecco’s
modified Eagle’s medium/F12 supplemented with 10% fetal
bovine serum. Once podocytes appeared, the cells were
trypsinized and placed in 24-well dishes. Replication-
deficient retrovirus containing human papiloma virus 16
E6/E7 DNA with a gentamycin resistant gene (a gift from Dr
Hong Yu), was added to each well in the presence of
polybrene (4 mg/ml). Twenty-four hours later, the medium
was changed and gentamycin (800 mg/ml) was added for 3
days to select those cells, which have incorporated the virus.
A parallel untreated sister well, served as a control. The cells
were grown to confluence in 24-well dishes and transferred
into T 75 flasks. Cells were trypsinized and exposed to
ZO1-FITC (fluorescein isothiocyante) as a primary antibody.
The cells were then placed over a column of microbeads
conjugated with anti-FITC. The cells were eluted from the
column and both immortalized and non-immortalized cells
were assayed for WT1mRNA, nephrin and transient receptor
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Figure 7 | MMP-2 and MMP-9 activity is increased in podocytes isolated from E2- and tamoxifen-treated db/db diabetic mice. Cell
lysates were collected in triplicate and normalized to cell number as described in Methods. Lysates were electrophoresed on zymogram gels
as described in Methods. MMP-2 and MMP-9 were increased in podocytes isolated from mice treated with E2 (lanes 4–6) and tamoxifen
(lanes 7–9) compared with placebo-treated mice (lanes 1–3). n¼ 2, *Po0.05, **Po0.005 E2 compared with placebo, #Po0.05 tamoxifen
compared with placebo.
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potential like channel 6 (TRCP-6) corrected in paper:
transient receptor potential-like channel 6 protein expression.
Real-time polymerase chain reaction
Amplification and measurement of target RNA was per-
formed on the ABI PRISM 7700 Sequence Detection System
as described earlier.54. The mRNA sequence was obtained
from the NCBI (National Center for Biotechnology Informa-
tion) to acquire the copy number for each ER subtype. The
number of occurrences of each of the four nucleobases was
counted and multiplied by its respective molecular weight.
These four numbers were then summed together to obtain
the mass of 1 mol of each subtype of the ER. The mass of the
purified plasmid of each subtype and the unknown samples
was calculated by the A260 method on a Molecular Devices
SpectraMax PLUS (Ramsey, MI, USA).
Western analysis
Western analysis on podocyte lysates for both the ER
subtypes was performed as described earlier.9 In addition,
podocyte cell lines were assessed for the expression of
nephrin protein using a rabbit polyclonal antibody against
the two first immunoglobulin G-like domains of human
nephrin (gifted by Dr Karl Tryggvason) and WT-1, ERK and
phosphorylated ERK (Santa Cruz Biotechnology, Santacruz,
CA, USA).
MMP-2 profile: MMP-2 and MMP-9 were analyzed by
zymography as described earlier.5
Statistical analysis
All values were expressed as mean±s.e.m. Significance of
differences between experimental groups was determined by
ANOVA (analysis of variance) in combination with Tukey’s
multiple comparison test. A P-value ofo0.05 was considered
significant.
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